绝经前激素受体阳性乳腺癌患者GnRHa长期管理专家共识(2026版)
绝经前激素受体阳性乳腺癌患者术后5年复发率可达20%~30%,GnRHa联合内分泌治疗是中高危患者的标准方案,推荐疗程为5年。中国抗癌协会乳腺癌专业委员会等机构遵循德尔菲法制定本共识,旨在规范GnRHa长期应用与管理。
要点
- 绝经前HR+乳腺癌术后5年复发率可达20%~30%。
- GnRHa联合内分泌治疗推荐疗程为5年,部分高危可延长。
- GnRHa长期应用可能导致依从性下降或不良事件增加。
核心结论
- GnRHa联合内分泌治疗是中高危绝经前HR+乳腺癌标准方案,推荐疗程5年,部分高危可考虑延长。
研究设计与样本
- 中国抗癌协会乳腺癌专业委员会等机构组织专家,基于国内外循证医学证据与中国临床实践,遵循德尔菲法制定本共识。
主要发现
- 绝经前HR+乳腺癌患者较绝经后肿瘤异质性更高、侵袭性更强、预后更差,术后5年复发率可达20%~30%。
- GnRHa长期应用(2~5年或>5年)可能导致治疗依从性下降或不良事件增加,进而可能影响患者预后。
关键数值与推荐
- GnRHa联合内分泌治疗推荐疗程为5年,部分高危患者可考虑延长治疗。
- GnRHa用药超过5年的适用人群、长期应用管理、药物转换策略尚缺乏统一规范。
临床怎么用
- 本共识旨在规范GnRHa的长期应用与管理,为临床医师提供参考,帮助患者完成既定疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Compared with postmenopausal patients, premenopausal patients with hormone receptor-positive (HR+) breast cancer generally exhibit higher tumor heterogeneity, greater invasiveness and a poorer prognosis, with a 5-year postoperative recurrence rate of 20%-30%. Endocrine therapy based on ovarian function suppression (OFS) is a key strategy to reduce the risk of recurrence, and gonadotropin-releasing hormone agonists (GnRHa) are commonly used agents for OFS in clinical practice. GnRHa combined with endocrine therapy has become the standard treatment regimen for intermediate- and high-risk premenopausal patients with HR+ breast cancer. The recommended treatment duration is 5 years, and extended treatment may be considered in selected high-risk patients. However, long-term GnRHa use (2-5 years or >5 years) may lead to decreased treatment adherence or increased adverse events, thereby potentially affecting patient prognosis. Furthermore, there is still a lack of standardization regarding the appropriate patient population for GnRHa use beyond 5 years, long-term management strategies, and drug switching approaches. To address these issues, the Committee of Breast Cancer Society of Chinese Anti-Cancer Association and other organizations convened a panel of experts to develop this consensus based on domestic and international evidence-based medical evidence and clinical practice in China, following the Delphi method. This consensus aims to standardize the long-term application and management of GnRHa, provide a reference for clinicians, help patients complete the planned treatment courses, and ultimately improve patients' quality of life and long-term prognosis. 绝经前激素受体阳性乳腺癌患者相较于绝经后患者,肿瘤异质性更高、侵袭性更强、预后更差,其术后5年复发率可达20%~30%。以卵巢功能抑制为基础的内分泌治疗是降低复发风险的关键策略,其中促性腺激素释放激素激动剂(GnRHa)为临床常用卵巢功能抑制药物。GnRHa联合内分泌治疗已成为中高危绝经前激素受体阳性患者的标准治疗方案,推荐疗程为5年,部分高危患者可考虑延长治疗。然而,GnRHa长期应用(2~5年或>5年)可能导致治疗依从性下降或不良事件增加,进而影响患者预后。此外,关于GnRHa用药超过5年的适用人群、长期应用管理、药物转换策略等方面尚缺乏统一规范。为此,中国抗癌协会乳腺癌专业委员会等机构组织专家,基于国内外循证医学证据与中国临床实践,遵循德尔菲法制定本共识,旨在规范GnRHa的长期应用与管理,为临床医师提供参考,帮助患者完成既定疗程,最终改善患者生活质量和远期预后。.
引用
- [Expert consensus on the long-term management of gonadotropin-releasing hormone agonists in premenopausal patients with hormone receptor-positive breast cancer (2026 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42477924. doi:10.3760/cma.j.cn112152-20260211-00089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。